GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into competition ...

Drugmaker GSK shared positive results Monday from two Phase 3 trials testing its inflammatory disease drug depemokimab in people with a condition known as chronic rhinosinusitis with nasal polyps.

IL-5 is present at high levels in nasal polyp tissue. IL-5 inhibitors play a key role in reducing type II inflammation. Year to date, shares of GSK have risen 5.5% against the industry’s decline ...

(Alliance News) - GSK PLC on Monday announced it has seen promising results from clinical trials investigating a potential treatment for chronic rhinosinusitis with nasal polyps, or CRSwNP.

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...

IL-5 is present at high levels in nasal polyp tissue. IL-5 inhibitors play a key role in reducing type II inflammation. Year to date, shares of GSK have risen 5.5% against the industry’s decline ...

UK-based pharmaceutical company GSK has announced positive results from the Phase III ANCHOR-1 and ANCHOR-2 clinical trials of depemokimab in adults with chronic rhinosinusitis with nasal polyps ...

has been launched in Sri Lanka by GlaxoSmithKline (GSK), the company said. Allergic rhinitis is an inflammation of the nasal passages that results in repetitive sneezing, rhinorrhea (runny nose), post ...